Oncology Learning Network

Ruth He, MD, discusses findings from a subgroup analysis assessing outcomes by primary tumor location in biliary tract cancer treated with durvalumab.

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Robert Jones, MD, University of Glasgow, UK, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following chemotherapy for patients with metastatic urothelial carcinoma who were negative for DNA repair biomarkers

Petros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer by HMP Global

Stay tuned for Part 2!

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Evolving Roles of KRAS Inhibitors in CRC by HMP Global

The Role of Tumor Mutation Burden Featuring Dr Morris by HMP Global

Dr Morris Discusses Emerging Targeted Therapies in mCRC by HMP Global

Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC.

Carla Casulo, MD, Associate Professor, Wilmot Cancer Institute, University of Rochester, New York, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed follicular lymphoma (FL).

Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II by HMP Global

Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer by HMP Global

Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC by HMP Global

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias.

John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with daratumumab, presented at the 2021 Annual ASH Meeting.

Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma by HMP Global

Charu Aggarwal, MD, Penn Medicine, Philadelphia, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.